Tag Archives: public policy

2011: A Pivotal Year for Biotechnology

Jim Greenwood

Biotechnology continues to hold the greatest promise to address many of the most critical issues facing our world. Continued innovation will lead to breakthrough new and improved cures and treatments for patients living with debilitating diseases such as cancer, HIV/AIDS, diabetes and Parkinson’s; enhanced agricultural products to feed a growing global population while protecting the environmental health of our planet; vaccines to protect against bioterrorism; and revolutionary biofuels. The ability of BIO members to continue Read More >

Jim's Corner  |  1 Comment  |  Email This Post
Tags: , ,

2012: A Critical Year for Biotechnology

Capitol

In 2012, we must continue to look for ways to reduce risk; enhance reward; reduce uncertainty; and reinforce the position of the industry as a major contributor resolving society’s most pressing needs. Policies to encourage investment in innovation and to speed discovery to scientific breakthroughs simply must be the priority in 2012. The industry relies on a policy and regulatory environment that encourages innovation for much needed treatments and cures for some of the most Read More >

Public Policy  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Biomedical Innovation: How the U.S. Can Stay Number One

lab_tech02-thumb

By Ross DeVol, chief research officer of the Milken Institute “The first step in winning the future is encouraging American innovation,” declared President Obama in his last State of the Union speech. A logical place to start is making sure that where we hold a lead, we keep it. Today, the U.S. has such a lead in biomedical innovation — the process of transforming scientific discoveries into vaccines, diagnostics, devices and therapies that improve and Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Medical Innovation at Risk

Scientists

The National Venture Capital Association’s MedIC Coalition recently released a report showing U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investments towards Europe and Asia. The report, Vital Signs: The Threat to Investment in U.S. Medical Innovation and the Imperative of FDA Reform, strongly indicates that America’s medical innovation economy is in grave danger of losing its primary source of funding, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Moving Beyond the Stem Cell Stalemate

Michael Werner

By Michael J. Werner, Alliance for Regenerative Medicine For the past several years, attendees at the World Stem Cell Summit have focused their energies primarily on legislative and legal efforts to protect human embryonic stem cell research. When folks gather at this year’s meeting, they will once again confront the reality that research opponents will continue to try to block these efforts. James Sherley has filed an appeal to the US Court of Appeals, DC Circuit Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,